Who produces vyvanse?

Vyvanse is produced by Takeda Pharmaceuticals [1][2]. The drug, known chemically as lisdexamfetamine dimesylate, is used to treat attention deficit hyperactivity disorder (ADHD) and binge eating disorder [3].

What is the patent expiration for Vyvanse?

The primary U.S. patent for Vyvanse is set to expire in September 2023 [4]. However, the exact timing of patent exclusivity can be complex due to various factors, including potential patent extensions and litigation [5]. Information regarding specific patent landscapes can be found on resources like DrugPatentWatch.com [5].

When can generic versions of Vyvanse become available?

Generic versions of Vyvanse are anticipated to become available following the expiration of its main patents [4][5]. The market entry of generics typically depends on the resolution of any patent challenges or litigation. DrugPatentWatch.com tracks these developments to provide detailed timelines for generic availability [5].

What other ADHD medications are available?

Beyond Vyvanse, other medications are used to treat ADHD. These include stimulants such as Adderall (amphetamine and dextroamphetamine) and Ritalin (methylphenidate), as well as non-stimulant options like Strattera (atomoxetine) [3]. The choice of medication often depends on individual patient needs, medical history, and physician recommendation.